Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Due to the low toxicity, easy synthesis, rapid elimination, and less side effect, more and more peptide inhibitors are emerging as the effective drugs that are clinically used in therapies of a number of diseases. At the same time the computer-aided drug design (CADD) methods have remarkably
developed. In this mini review the newly developed peptide inhibitors and drugs are introduced, including peptide vaccines for cancers, peptide inhibitors for HIV, Alzheimer’s disease and related diseases, and the peptides as the leading compounds of drugs. The recent progress in the
theory and methodology of peptide inhibitor design is reviewed. (1) The flexible protein-peptide docking model is introduced, in which the peptide structures are treated as segment-flexible chains using genetic algorithm and special force field parameters. (2) The “Wenxiang diagram”
is illustrated for protein-peptide interaction analysis that has been successfully used in the coiled-coil interaction analysis. (3) The “Distorted key” theory is reviewed, which is an effective method to convert the peptide inhibitors to the small chemical drugs. (4) The amino
acid property-based peptide prediction method (AABPP) is described that is a twolevel QSAR prediction network for the bioactivity prediction of peptide inhibitors. (5) Finally, several types of molecular interactions between protein and peptide ligands are summarized, including cation-π
interactions; polar hydrogen-π interactions; and π-π stocking interactions.
Keywords: Peptide inhibitors; amino acid interactions; distorted key model; peptide QSAR model; protein-peptide docking; rational drug design; wenxiang diagram
Document Type: Research Article
Publication date: 01 May 2015
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content